TCTMD - tctmd.com
WEBGiven the growing prevalence of heart failure worldwide, we recognize a clear mandate for developing new monitoring strategies and treatment options to increase survival, decrease hospitalizations, and improve quality of life — and for achieving these goals via a variety of potential interventions that target the various contributors to heart ...
Blood Pressure Insights in COVID-19: Watch for Drops and RAAS …
WEBSep 10, 2020 · Here, Baher Al-Abbasi, MD (University of Miami/JFK Medical Center, Atlantis, FL), and colleagues noted increased in-hospital mortality in 172 COVID-19 patients taking ACE inhibitors or ARBs compared with those not taking the drugs (33% vs 13%; P = 0.003), as well as increased likelihood of admission to the …
Bentracimab Swiftly Reverses Ticagrelor, Platelet-Function Study ...
WEBApr 2, 2022 · WASHINGTON, DC—Additional evidence, this time from a phase IIb trial in healthy people ages 50 to 80, supports that bentracimab (PhaseBio) provides a near-immediate reversal of ticagrelor’s antiplatelet effects evaluated using platelet function tests. The investigational recombinant human monoclonal antibody fragment binds to free ...
Slides | tctmd.com
WEBApr 8, 2024 · Interventional Complications 2023. Seattle, WA. July 14. July 15, 2023. See All Conferences. The best online resource for cardiology conference slides around the globe.
News | tctmd.com
WEBSubcutaneous Furosemide Enables HF Patients to Address Congestion at Home. The AT HOME-HF pilot study suggests this approach to diuretic delivery can safely improve symptoms and function. By Caitlin E. Cox. September 16, 2024.
Loading Dose Smooths Switch From Ticagrelor to Clopidogrel …
WEBMar 20, 2018 · By Yael L. Maxwell. ORLANDO, FL—Patients with coronary artery disease who need to switch from ticagrelor to clopidogrel after PCI should receive a loading dose of 600 mg clopidogrel between 12 and 24 hours following ticagrelor discontinuation, according to results from a randomized, pharmacodynamic study. Findings from the …
TCT 2024 - TCTMD.com
WEBTCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
Nitrates and Erectile Dysfunction Meds? Increasingly Common, …
WEBApr 20, 2022 · By L.A. McKeown. Despite widely publicized warnings about the potential interaction between nitrates prescribed for angina and oral (phosphodiesterase type 5) PDE5 inhibitors taken for erectile dysfunction, a Danish study suggests that prescriptions for the latter have steadily increased over the last 20 years in men who take nitrates, but ...
TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without …
WEBSep 26, 2019 · SAN FRANCISCO, CA (UPDATED)—Dropping aspirin after 3 months of dual antiplatelet therapy (DAPT) with ticagrelor (Brilinta, AstraZeneca) following PCI among high-risk patients is associated with lower rates of bleeding but no increased risk of death, MI, or stroke, according to results of the double-blind, placebo-controlled TWILIGHT trial.
Safe to Upgrade From Pacemaker or Defibrillator to CRT
WEBFeb 10, 2021 · Upgrading a patient from an existing permanent pacemaker or implantable cardioverter-defibrillator (ICD) to a cardiac resynchronization therapy (CRT) device can be successfully and safely done in the hands of experienced operators, according to a new analysis from a large tertiary center. When compared with …
Skip to content